Brian Johnson
Research Subjects
Brian Johnson has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Eric Merrell
SUNY Upstate Medical University
3 shared publicationsYanli Zhang-James
Department of Psychiatry and Behavioral Sciences, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States
3 shared publicationsMichael Kirsch
Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, NY, United States
2 shared publicationsStephen Faraone
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, United States
2 shared publications- Stephen V. Faraone
Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, USA
2 shared publications Swati Shivale
Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, United States
2 shared publications
Latest Publications
- Open Access
- 19 June 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1409284
Recovery from opioid use on a neuropsychoanalytic service
Background: Little is known about recovery from opioid use disorder (OUD) or outcomes of detoxification and drug-free treatment of chronic opioid therapy (COT). Harm reduction with medications for opioid use disorder (MOUD) is regarded as the only legitimate treatment.Methods: The Institutional Review Board (IRB) approved reporting deidentified outcomes. Patients seen over a 10-year period whose records suggested recovery were called and interviewed.Results: Overall, 69/86 (80%) confirmed that they had been sober for at least a year, including 41 patients with OUD (75%) and 28 COT patients (90%). 91% were drug-free, and 9% were on MOUD. 79% preferred a psychotherapy approach. 21% preferred MOUD. Coming for more treatment and abstinence from tobacco were significantly correlated with recovery.Conclusion: This is the first report that we are aware of regarding the frequency of recovery from OUD and COT. We have complicated the discussion about what is the best treatment for patients with OUD and patients on COT. Advising that maintenance is the only legitimate treatment for patients who suffer from OUD or who are on COT seems both premature and jeopardizes the ability of treaters to individualize treatment recommendations.
- 19 June 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1409284
Open AccessRecovery from opioid use on a neuropsychoanalytic service
Background: Little is known about recovery from opioid use disorder (OUD) or outcomes of detoxification and drug-free treatment of chronic opioid therapy (COT). Harm reduction with medications for opioid use disorder (MOUD) is regarded as the only legitimate treatment.Methods: The Institutional Review Board (IRB) approved reporting deidentified outcomes. Patients seen over a 10-year period whose records suggested recovery were called and interviewed.Results: Overall, 69/86 (80%) confirmed that they had been sober for at least a year, including 41 patients with OUD (75%) and 28 COT patients (90%). 91% were drug-free, and 9% were on MOUD. 79% preferred a psychotherapy approach. 21% preferred MOUD. Coming for more treatment and abstinence from tobacco were significantly correlated with recovery.Conclusion: This is the first report that we are aware of regarding the frequency of recovery from OUD and COT. We have complicated the discussion about what is the best treatment for patients with OUD and patients on COT. Advising that maintenance is the only legitimate treatment for patients who suffer from OUD or who are on COT seems both premature and jeopardizes the ability of treaters to individualize treatment recommendations.
- Open Access
- 21 September 2023
- Published by Springer Nature in Research Square
Opioid induced hyperalgesia treated with low dose naltrexone improves pain
Opioids are prescribed for 5 – 8 million Americans with chronic pain1 and many more worldwide. For patients currently on chronic opioid therapy (COT) continuation of opioids is recommended because of mental health crises and overdoses that occur during medication taper2 and because of deaths associated with accidental overdose when opioid medications are discontinued.3, 4 Because opioid medications are exogenous opioid hormones that downregulate the pain damping opioid receptor system and upregulate pain drivers, opioid induced hyperalgesia (OIH) is a near-universal finding when the cold pressor test (CPT) is used to measure pain tolerance.5 Detoxification is best accomplished with a single dose of buprenorphine immediately followed with low dose naltrexone (LDN). LDN treats OIH. We conducted a retrospective chart review of patients treated on our pain service from 2011 through 2022. Short CPTs improved with detoxification and LDN. Pain diminished. Our results show that opioid medications are contraindicated for chronic pain. Patients currently prescribed daily opioid medications can safely be detoxified and have their centrally mediated pain treated with LDN, using the CPT to track resolution of OIH. Psychotherapy is necessary in many instances because opioids attenuate feelings and distort relationships.
- 21 September 2023
- Published by Springer Nature in Research Square
Open AccessOpioid induced hyperalgesia treated with low dose naltrexone improves pain
Opioids are prescribed for 5 – 8 million Americans with chronic pain1 and many more worldwide. For patients currently on chronic opioid therapy (COT) continuation of opioids is recommended because of mental health crises and overdoses that occur during medication taper2 and because of deaths associated with accidental overdose when opioid medications are discontinued.3, 4 Because opioid medications are exogenous opioid hormones that downregulate the pain damping opioid receptor system and upregulate pain drivers, opioid induced hyperalgesia (OIH) is a near-universal finding when the cold pressor test (CPT) is used to measure pain tolerance.5 Detoxification is best accomplished with a single dose of buprenorphine immediately followed with low dose naltrexone (LDN). LDN treats OIH. We conducted a retrospective chart review of patients treated on our pain service from 2011 through 2022. Short CPTs improved with detoxification and LDN. Pain diminished. Our results show that opioid medications are contraindicated for chronic pain. Patients currently prescribed daily opioid medications can safely be detoxified and have their centrally mediated pain treated with LDN, using the CPT to track resolution of OIH. Psychotherapy is necessary in many instances because opioids attenuate feelings and distort relationships.
- Open Access
- 19 August 2023
- Published by Springer Nature in Research Square
Effective Outpatient Alcohol Detoxification on a Neuropsychoanalytic Service
Consumption of alcohol causes 3 million deaths per year worldwide.1 Detoxification is expensive in terms of personnel time and cost. Most patients do not engage in aftercare. We examined records from a neuropsychoanalytic addiction medicine service to determine whether severe alcohol withdrawal can be managed outpatient. Valproic acid 2000 mg was immediately given and chlordiazepoxide, if needed, was given every hour until withdrawal was in remission. 42 patients had a total of 69 detoxifications. The prediction of alcohol withdrawal symptom severity (PAWSS) rated moderate or severe withdrawal for 86%. For 78% withdrawal remitted in 3.5 hours or less. Completion was 97%. 100% of patients had at least 4 follow up visits. Valproate and chlordiazepoxide loading by the same outpatient providers who treat after detoxification is safe, cheap, effective, and humane. The requirement that a sober support person attend the initial assessment and accompany the patient during detoxification addresses denial of the need for help and in many cases, extends recovery to the family. Having observed disulfiram administration for the first year sober stabilizes patients who otherwise might respond to craving and drinking dreams with relapse. These results indicate that outpatient alcohol detoxification may be comparable or better than inpatient treatment in facilitating abstinence from alcohol.
- 19 August 2023
- Published by Springer Nature in Research Square
Open AccessEffective Outpatient Alcohol Detoxification on a Neuropsychoanalytic Service
Consumption of alcohol causes 3 million deaths per year worldwide.1 Detoxification is expensive in terms of personnel time and cost. Most patients do not engage in aftercare. We examined records from a neuropsychoanalytic addiction medicine service to determine whether severe alcohol withdrawal can be managed outpatient. Valproic acid 2000 mg was immediately given and chlordiazepoxide, if needed, was given every hour until withdrawal was in remission. 42 patients had a total of 69 detoxifications. The prediction of alcohol withdrawal symptom severity (PAWSS) rated moderate or severe withdrawal for 86%. For 78% withdrawal remitted in 3.5 hours or less. Completion was 97%. 100% of patients had at least 4 follow up visits. Valproate and chlordiazepoxide loading by the same outpatient providers who treat after detoxification is safe, cheap, effective, and humane. The requirement that a sober support person attend the initial assessment and accompany the patient during detoxification addresses denial of the need for help and in many cases, extends recovery to the family. Having observed disulfiram administration for the first year sober stabilizes patients who otherwise might respond to craving and drinking dreams with relapse. These results indicate that outpatient alcohol detoxification may be comparable or better than inpatient treatment in facilitating abstinence from alcohol.
- Open Access
- 7 August 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (6) , 532-538
Daily cannabis use may cause cannabis‐induced hyperalgesia
Background and Objectives: Public opinion about cannabis as a medical treatment is generally favorable. As many as 35% of primary care patients report medical use of cannabis, most commonly for pain treatment. We designed a way to test whether cannabis helps chronic pain.Methods: A retrospective cohort study was conducted to explore whether daily long‐term cannabis use was associated with increased pain sensitivity using the cold pressor test (CPT) to measure pain tolerance. Patients who used cannabis every day were compared to patients who inhaled tobacco and control patients who never used tobacco or cannabis. The effect of cannabis use on CPT was assessed using a generalized linear model.Results: Patients using cannabis daily had a median CPT of 46 s, similar to those who did not use cannabis but who inhaled tobacco (median CPT 45 s). Patients who used both cannabis and tobacco had the lowest CPT (median 26 s). The control group had a median CPT of 105 s. Cannabis use was associated with a significantly decreased pain tolerance (χ²(1) = 8.0, p = .004). The effect of tobacco on CPT was only marginally significant (χ²(1) = 3.8, p = .052).Conclusion and Scientific Significance: This suggests a phenomenon similar to opioid‐induced hyperalgesia; a drug that reduces pain short term, induces pain long term—opponent process. Daily cannabis use may make chronic pain worse over time by reducing pain tolerance. In terms of risk/benefit, daily cannabis users risk addiction without any long‐term benefit for chronic pain.
- 7 August 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (6) , 532-538
Open AccessDaily cannabis use may cause cannabis‐induced hyperalgesia
Background and Objectives: Public opinion about cannabis as a medical treatment is generally favorable. As many as 35% of primary care patients report medical use of cannabis, most commonly for pain treatment. We designed a way to test whether cannabis helps chronic pain.Methods: A retrospective cohort study was conducted to explore whether daily long‐term cannabis use was associated with increased pain sensitivity using the cold pressor test (CPT) to measure pain tolerance. Patients who used cannabis every day were compared to patients who inhaled tobacco and control patients who never used tobacco or cannabis. The effect of cannabis use on CPT was assessed using a generalized linear model.Results: Patients using cannabis daily had a median CPT of 46 s, similar to those who did not use cannabis but who inhaled tobacco (median CPT 45 s). Patients who used both cannabis and tobacco had the lowest CPT (median 26 s). The control group had a median CPT of 105 s. Cannabis use was associated with a significantly decreased pain tolerance (χ²(1) = 8.0, p = .004). The effect of tobacco on CPT was only marginally significant (χ²(1) = 3.8, p = .052).Conclusion and Scientific Significance: This suggests a phenomenon similar to opioid‐induced hyperalgesia; a drug that reduces pain short term, induces pain long term—opponent process. Daily cannabis use may make chronic pain worse over time by reducing pain tolerance. In terms of risk/benefit, daily cannabis users risk addiction without any long‐term benefit for chronic pain.
- 18 October 2022
- Published by Springer Nature
- p. 1059-1075
Using New Technology and Concepts on the Oldest Addiction on Earth, Alcoholism
- 18 October 2022
- Published by Springer Nature
- p. 1059-1075
Using New Technology and Concepts on the Oldest Addiction on Earth, Alcoholism
- Open Access
- 26 September 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 870415
Drive, instinct, reflex—Applications to treatment of anxiety, depressive and addictive disorders
The neuropsychoanalytic approach solves important aspects of how to use our understanding of the brain to treat patients. We describe the neurobiology underlying motivation for healthy behaviors and psychopathology. We have updated Freud’s original concepts of drive and instinct using neuropsychoanalysis in a way that conserves his insights while adding information that is of use in clinical treatment. Drive (Trieb) is a pressure to act on an internal stimulus. It has a motivational energic source, an aim, an object, and is terminated by the satisfaction of a surge of serotonin. An instinct (Instinkt) is an inherited pattern of behavior that varies little from species to species. Drives are created by internal/ventral brain factors. Instincts require input from the outside that arrive through dorsal brain structures. In our model unpleasure is the experience of unsatisfied drives while pleasure if fueled by a propitious human environment. Motivational concepts can be used guide clinical work. Sometimes what had previously described psychoanalytically as, “Internal conflict,” can be characterized neurobiologically as conflicts between different motivational systems. These motivational systems inform treatment of anxiety and depression, addiction in general and specific problems of opioid use disorder. Our description of motivation in addictive illness shows that the term, “reward system,” is incorrect, eliminating a source of stigmatizing addiction by suggesting that it is hedonistic. Understanding that motivational systems that have both psychological and brain correlates can be a basis for treating various disorders. Over many papers the authors have described the biology of drives, instincts, unpleasure and pleasure. We will start with a summary of our work, then show its clinical application.
- 26 September 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 870415
Open AccessDrive, instinct, reflex—Applications to treatment of anxiety, depressive and addictive disorders
The neuropsychoanalytic approach solves important aspects of how to use our understanding of the brain to treat patients. We describe the neurobiology underlying motivation for healthy behaviors and psychopathology. We have updated Freud’s original concepts of drive and instinct using neuropsychoanalysis in a way that conserves his insights while adding information that is of use in clinical treatment. Drive (Trieb) is a pressure to act on an internal stimulus. It has a motivational energic source, an aim, an object, and is terminated by the satisfaction of a surge of serotonin. An instinct (Instinkt) is an inherited pattern of behavior that varies little from species to species. Drives are created by internal/ventral brain factors. Instincts require input from the outside that arrive through dorsal brain structures. In our model unpleasure is the experience of unsatisfied drives while pleasure if fueled by a propitious human environment. Motivational concepts can be used guide clinical work. Sometimes what had previously described psychoanalytically as, “Internal conflict,” can be characterized neurobiologically as conflicts between different motivational systems. These motivational systems inform treatment of anxiety and depression, addiction in general and specific problems of opioid use disorder. Our description of motivation in addictive illness shows that the term, “reward system,” is incorrect, eliminating a source of stigmatizing addiction by suggesting that it is hedonistic. Understanding that motivational systems that have both psychological and brain correlates can be a basis for treating various disorders. Over many papers the authors have described the biology of drives, instincts, unpleasure and pleasure. We will start with a summary of our work, then show its clinical application.
- 10 April 2022
- Published by Springer Nature
- p. 1-17
Using New Technology and Concepts on the Oldest Addiction on Earth, Alcoholism
- 10 April 2022
- Published by Springer Nature
- p. 1-17
Using New Technology and Concepts on the Oldest Addiction on Earth, Alcoholism
- Open Access
- 28 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22677
Depression in Fibromyalgia Patients May Require Low-Dose Naltrexone to Respond: A Case Report
Fibromyalgia and depression are frequently comorbid. We propose a hormonal system model in understanding the underlying endogenous opioid system dysregulation in fibromyalgia with the utilization of the cold pressor test (CPT) in clinical practice to monitor treatment response to low-dose naltrexone (LDN) and the subsequent remission of major depressive disorder by restoring opioid tone. A 60-year-old professional on permanent disability presented with refractory depression and chronic widespread pain after years of multiple failed medication trials. Rating scales confirmed severe depression, Hamilton Rating Scale for Depression (HAM-D) of 20, a short cold pressor test (CPT) time of 21 seconds, and a face pain scale (FPS) of 8/10. Physical examination assessing for fibromyalgia was diagnostic, with 18/18 positive tender points. LDN, a minor increase in trazodone, and transference-focused psychotherapy were employed. The patient’s CPT time increased modestly. The patient achieved remission of both conditions in 10 weeks when both disorders were treated at once (FPS and HAM-D of zero), restoring the quality of life, relatedness, and motivation. Some fibromyalgia patients may achieve remission of comorbid depression with concomitant low-dose naltrexone (LDN) treatment that is widely used “off label” to treat pain. LDN is a promising alternative for the treatment of chronic pain in fibromyalgia with its safety profile, high tolerability, and absence of abuse potential. Our unique finding is that without successful LDN treatment of fibromyalgia, remission of depression may be unlikely.
- 28 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22677
Open AccessDepression in Fibromyalgia Patients May Require Low-Dose Naltrexone to Respond: A Case Report
Fibromyalgia and depression are frequently comorbid. We propose a hormonal system model in understanding the underlying endogenous opioid system dysregulation in fibromyalgia with the utilization of the cold pressor test (CPT) in clinical practice to monitor treatment response to low-dose naltrexone (LDN) and the subsequent remission of major depressive disorder by restoring opioid tone. A 60-year-old professional on permanent disability presented with refractory depression and chronic widespread pain after years of multiple failed medication trials. Rating scales confirmed severe depression, Hamilton Rating Scale for Depression (HAM-D) of 20, a short cold pressor test (CPT) time of 21 seconds, and a face pain scale (FPS) of 8/10. Physical examination assessing for fibromyalgia was diagnostic, with 18/18 positive tender points. LDN, a minor increase in trazodone, and transference-focused psychotherapy were employed. The patient’s CPT time increased modestly. The patient achieved remission of both conditions in 10 weeks when both disorders were treated at once (FPS and HAM-D of zero), restoring the quality of life, relatedness, and motivation. Some fibromyalgia patients may achieve remission of comorbid depression with concomitant low-dose naltrexone (LDN) treatment that is widely used “off label” to treat pain. LDN is a promising alternative for the treatment of chronic pain in fibromyalgia with its safety profile, high tolerability, and absence of abuse potential. Our unique finding is that without successful LDN treatment of fibromyalgia, remission of depression may be unlikely.
- Open Access
- 10 June 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12
Drive and Instinct—How They Produce Relatedness and Addiction
Addictive drugs are responsible for mass killing. Neither persons with addiction nor the general populace seem conscious of the malevolence of governments and drug dealers working together. How could this be? What is the place of psychoanalysis in thinking about deaths from addiction and in responding to patients with addiction? To answer these questions, we revise concepts of SEEKING, drive, instinct, pleasure, and unpleasure as separable. We review the neurobiological mechanism of cathexis. We discuss how addictive drugs take over the will by changing the SEEKING system. We review how opioid tone in the central nervous system regulates human relationships and how this endogenous hormonal system is modified by external opioid administration. We differentiate the pleasure of relatedness from the unpleasure of urgent need including the urgent need for drugs. We show how addictive drug-induced changes in the SEEKING system diminish dopaminergic tone, reducing the motivation to engage in the pursuit of food, water, sex, sleep, and relationships in favor of addictive drugs. With this neuropsychoanalytic understanding of how drugs work, we become more confidently conscious of our ability to respond individually and socially.
- 10 June 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12
Open AccessDrive and Instinct—How They Produce Relatedness and Addiction
Addictive drugs are responsible for mass killing. Neither persons with addiction nor the general populace seem conscious of the malevolence of governments and drug dealers working together. How could this be? What is the place of psychoanalysis in thinking about deaths from addiction and in responding to patients with addiction? To answer these questions, we revise concepts of SEEKING, drive, instinct, pleasure, and unpleasure as separable. We review the neurobiological mechanism of cathexis. We discuss how addictive drugs take over the will by changing the SEEKING system. We review how opioid tone in the central nervous system regulates human relationships and how this endogenous hormonal system is modified by external opioid administration. We differentiate the pleasure of relatedness from the unpleasure of urgent need including the urgent need for drugs. We show how addictive drug-induced changes in the SEEKING system diminish dopaminergic tone, reducing the motivation to engage in the pursuit of food, water, sex, sleep, and relationships in favor of addictive drugs. With this neuropsychoanalytic understanding of how drugs work, we become more confidently conscious of our ability to respond individually and socially.
- Open Access
- 24 May 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12
Autism Case Report: Cause and Treatment of “High Opioid Tone” Autism
Introduction: Neurobiological systems engineering models are useful for treating patients. We show a model of “high opioid tone” autism and present a hypothesis about how autism is caused by administration of opioids during childbirth.Main Symptoms: Clinical diagnosis of autism in a 25 year old man was confirmed by a Social Responsiveness Scale (SRS) self-rating of 79, severe, and a Social Communications Questionnaire (SCQ-2) by the patient's father scoring 27. Cold pressor time (CPT) was 190 seconds—unusually long, consonant with the high pain tolerance of autism.Therapeutic Intervention and Outcomes: At naltrexone 50 mg/day SRS fell to 54 and SCQ-−2–9; both non-significant. CPT fell to 28, repeat 39 s. Improved relatedness was experienced ambivalently, understood as feelings never before experienced—causing pain. Non-compliance with naltrexone was followed by cutting open his palm and drinking alcoholically. Transference focused psychotherapy has helped him remain naltrexone—compliant while he works on issues of identity and relatedness.Conclusion: The model suggests studies that could be conducted to both prevent and treat this form of autism.
- 24 May 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12
Open AccessAutism Case Report: Cause and Treatment of “High Opioid Tone” Autism
Introduction: Neurobiological systems engineering models are useful for treating patients. We show a model of “high opioid tone” autism and present a hypothesis about how autism is caused by administration of opioids during childbirth.Main Symptoms: Clinical diagnosis of autism in a 25 year old man was confirmed by a Social Responsiveness Scale (SRS) self-rating of 79, severe, and a Social Communications Questionnaire (SCQ-2) by the patient's father scoring 27. Cold pressor time (CPT) was 190 seconds—unusually long, consonant with the high pain tolerance of autism.Therapeutic Intervention and Outcomes: At naltrexone 50 mg/day SRS fell to 54 and SCQ-−2–9; both non-significant. CPT fell to 28, repeat 39 s. Improved relatedness was experienced ambivalently, understood as feelings never before experienced—causing pain. Non-compliance with naltrexone was followed by cutting open his palm and drinking alcoholically. Transference focused psychotherapy has helped him remain naltrexone—compliant while he works on issues of identity and relatedness.Conclusion: The model suggests studies that could be conducted to both prevent and treat this form of autism.